Ever wonder why acquisition-minded CEO John Lechleiter has been cool to the idea of Eli Lilly and Co. buying Amylin Pharmaceuticals Inc., Lilly’s partner on the diabetes medicine Byetta? One reason might be that Lilly is developing its own entrant into the promising new class of GLP-1 diabetes drugs, which was pioneered by the 2005 […]
Eli Lilly and Co. has joined three of its fiercest rivals to invest $40 million in a Massachusetts-based biotech company with potentially breakthrough drug technology. Aileron Therapeutics announced the funding Monday from Indianapolis-based Lilly, as well as Novartis AG and Roche Holding AG, both based in Switzerland, and GlaxoSmithKline PLC, based in the United Kingdom. […]
By J.K. [email protected] Eli Lilly and Co. has joined three of its fiercest rivals to invest $40 million in a Massachusetts-based biotech company with potentially breakthrough drug technology. Aileron Therapeutics announced the funding Monday from Indianapolis-based Lilly, as well as Novartis AG and Roche Holding AG, both based in Switzerland, and GlaxoSmithKline PLC, based in […]
Advisers to the Food and Drug Administration said yesterday that three blockbuster psychiatric drugs appear safe and effective for children and adolescents, despite side effects that can increase the risk of diabetes. The FDA’s panel of psychiatric experts voted to approve the use of drugs from AstraZeneca, Eli Lilly and Pfizer for treating schizophrenia and […]
Gus Watanabe, the chairman of BioCrossroads Inc., died Tuesday night. The central Indiana life sciences development group confirmed his death this morning. “We’re incredibly saddened by the loss of our friend and colleague,” said BioCrossroads spokeswoman Lori Leroy. Watanabe, 67, the former president of the research arm of Eli Lilly and Co., joined BioCrossroads as […]
Gus Watanabe, the chairman of BioCrossroads Inc., died Tuesday night. The life sciences development group confirmed his death this morning. “We’re incredibly saddened by the loss of our friend and colleague,” said BioCrossroads spokeswoman Lori Leroy. Watanabe, 67, the former president of the research arm of Eli Lilly and Co., joined BioCrossroads as chairman in […]
The unexpected death Tuesday evening of Dr. August “Gus” Watanabe leaves a large hole in the hearts of his friends and in the heart of the life sciences industry in central Indiana. Watanabe died of a self-inflicted gunshot wound at his Brown County cabin, according to the Brown County Sheriff’s Department. Watanabe, 67, was chairman […]
The unexpected death Tuesday evening of Dr. August “Gus” Watanabe leaves a large hole in the hearts of his friends and in the heart of the life sciences industry in central Indiana. Watanabe died of a self-inflicted gunshot wound at his Brown County cabin, according to the Brown County Sheriff’s Department. Watanabe, 67, was chairman […]
Eli Lilly and Co. isn’t the only company to set aside a day for volunteering. The Big 4 accounting firm Deloitte had its 10th
annual IMPACT Day June 5.
While Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it’s developing a potential
competitor to Byetta all on its own.
Eli Lilly and Co. has launched a Web portal to help it more easily find, evaluate and possibly license experimental drugs discovered by researchers at universities and biotechnology companies, the Indianapolis-based drugmaker announced today. Lilly hopes the program behind the portal, called the Lilly Phenotypic Drug Discovery Initiative, or PD2, opens up an untapped source […]
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories – low-cost and all over the world. Bill Scott and Martin O’Donnell have started a project called Distributed Drug Discovery, trying to lure in researchers and students at universities around the globe to collaborate over the Internet to discover new drugs. […]
Beaverton, Ore.-based athletic footwear and apparel maker Nike Inc. said today it named Eli Lilly and Co. CEO John C. Lechleiter to its board of directors. Lechleiter, 55, was named president and CEO of Indianapolis-based Eli Lilly in 2008 and became chairman of the board in 2009. “John’s combination of executive leadership and expertise leading […]
Hope and fear mix in Paul Nysewander when he considers President Barack Obama’s controversial idea to set up a new governmentrun health insurance plan. The owner of a three-person accounting firm, Nysewander says there’s significant appeal in having a public plan as a new option for health insurance. “As long as it remains an option,” […]
An exaggerated share of the nation’s wealth is paid to CEOs of public companies, their minions and directors, through agreements
made inside boardrooms, by highly compensated individuals who commit shareholders’ money and are not subject to effective
oversight.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—a model that’s low-cost
and can spread around the world.
Businesses all want to see reform of the health care system, but they diverge on how much the U.S. government’s entrance into
the insurance market would help or hurt them.
President Barack Obama today welcomed the pharmaceutical industry’s agreement to help close a gap in Medicare’s drug coverage, calling the pact a step forward in the push for an overhaul of the nation’s health care system. Obama said that drug companies have pledged to spend $80 billion over the next decade to help reduce the […]
The past decade has often been rough for Eli Lilly and Co., but a new economic impact study commissioned by the company suggests the drugmaker’s contribution to the state’s economy has actually increased over that time. The new study by an Indiana University professor calculates that Lilly accounts for $8 billion, or 3.3 percent, of […]
Indianapolis has always had Eli Lilly and Co., it seems, and Lilly always seems to care for Indianapolis
like a rich uncle.
People employed directly by Lilly and by companies doing business with Lilly account for about one of every
30…
